In This Article:
Over the last 7 days, the United States market has dropped 1.1%, yet it remains up by 9.1% over the past year with earnings forecasted to grow by 14% annually. In this context, identifying high growth tech stocks that can capitalize on these positive earnings projections is crucial for investors seeking opportunities in a dynamic and evolving sector.
Top 10 High Growth Tech Companies In The United States
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| Super Micro Computer | 26.38% | 39.09% | ★★★★★★ |
| Ardelyx | 20.78% | 59.46% | ★★★★★★ |
| Travere Therapeutics | 26.41% | 64.47% | ★★★★★★ |
| Blueprint Medicines | 21.36% | 61.45% | ★★★★★★ |
| TG Therapeutics | 26.46% | 38.75% | ★★★★★★ |
| Alnylam Pharmaceuticals | 23.65% | 61.11% | ★★★★★★ |
| AVITA Medical | 27.28% | 60.66% | ★★★★★★ |
| Alkami Technology | 20.54% | 76.67% | ★★★★★★ |
| Ascendis Pharma | 35.16% | 60.26% | ★★★★★★ |
| Lumentum Holdings | 21.59% | 110.32% | ★★★★★★ |
Click here to see the full list of 235 stocks from our US High Growth Tech and AI Stocks screener.
Below we spotlight a couple of our favorites from our exclusive screener.
ARS Pharmaceuticals
Simply Wall St Growth Rating: ★★★★★☆
Overview: ARS Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for severe allergic reactions, with a market cap of $1.41 billion.
Operations: ARS Pharmaceuticals specializes in creating and marketing therapies for acute allergic responses. The company operates with a market capitalization of approximately $1.41 billion.
ARS Pharmaceuticals has shown a dynamic shift in its market approach, particularly with the recent FDA approval and commercialization of neffy, a needle-free epinephrine nasal spray. This innovation not only diversifies their product line but also taps into a critical need for safer, more accessible treatments for life-threatening allergic reactions. The company's strategic partnership with ALK-Abello to target up to 9,000 pediatricians underscores its aggressive marketing and expansion strategy. Despite a significant net loss reported in Q1 2025 of $33.94 million, ARS Pharmaceuticals is poised for growth with expected revenue increases driven by neffy's adoption and potential market penetration during the critical back-to-school season.
-
Unlock comprehensive insights into our analysis of ARS Pharmaceuticals stock in this health report.
-
Explore historical data to track ARS Pharmaceuticals' performance over time in our Past section.
CyberArk Software
Simply Wall St Growth Rating: ★★★★☆☆
Overview: CyberArk Software Ltd. is a company that specializes in developing and selling software-based identity security solutions and services across various regions globally, with a market capitalization of approximately $17.87 billion.